Myeloid-derived suppressor cell heterogeneity and subset definition
- PMID: 20171075
- DOI: 10.1016/j.coi.2010.01.021
Myeloid-derived suppressor cell heterogeneity and subset definition
Abstract
Myeloid derived suppressor cells (MDSCs) are defined in mice on the basis of CD11b and Gr-1 marker expression and the functional ability to inhibit T lymphocyte activation. Nevertheless the term 'heterogeneous' remains the first, informal feature commonly attributed to this population. It is clear that CD11b(+)Gr-1(+) cells are part of a myeloid macropopulation, which comprises at least two subsets of polymorphonuclear and monocytic cells with different immunosuppressive properties. While recent literature shows substantial agreement on the immunoregulatory property of the monocytic MDSC subset, there is still contrasting evidence on the role of the granulocytic fraction. Moreover, this dichotomy holds true for human MDSCs. We attempt here to summarize conflicting findings in the field and provide some possible, unifying explanations.
Copyright 2010 Elsevier Ltd. All rights reserved.
Similar articles
-
Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF.Eur J Immunol. 2010 Jan;40(1):22-35. doi: 10.1002/eji.200939903. Eur J Immunol. 2010. PMID: 19941314
-
CD49d is a new marker for distinct myeloid-derived suppressor cell subpopulations in mice.J Immunol. 2010 Jul 1;185(1):203-10. doi: 10.4049/jimmunol.0903573. Epub 2010 Jun 4. J Immunol. 2010. PMID: 20525890
-
Myeloid-derived suppressor cell activation by combined LPS and IFN-gamma treatment impairs DC development.Eur J Immunol. 2009 Oct;39(10):2865-76. doi: 10.1002/eji.200939486. Eur J Immunol. 2009. PMID: 19637228
-
Myeloid derived suppressor cells and their role in tolerance induction in cancer.J Dermatol Sci. 2010 Jul;59(1):1-6. doi: 10.1016/j.jdermsci.2010.05.001. J Dermatol Sci. 2010. PMID: 20570112 Review.
-
Myeloid-derived suppressor cells--their role in haemato-oncological malignancies and other cancers and possible implications for therapy.Br J Haematol. 2011 Jun;153(5):557-67. doi: 10.1111/j.1365-2141.2011.08678.x. Epub 2011 Apr 8. Br J Haematol. 2011. PMID: 21477210 Review.
Cited by
-
Inflammatory networks and immune surveillance of pancreatic carcinoma.Curr Opin Immunol. 2013 Apr;25(2):200-5. doi: 10.1016/j.coi.2013.01.006. Epub 2013 Feb 17. Curr Opin Immunol. 2013. PMID: 23422836 Free PMC article. Review.
-
Tumor-associated myeloid cells can be activated in vitro and in vivo to mediate antitumor effects.Cancer Immunol Immunother. 2012 Oct;61(10):1683-97. doi: 10.1007/s00262-012-1236-2. Epub 2012 Mar 6. Cancer Immunol Immunother. 2012. PMID: 22392192 Free PMC article.
-
A novel tumor-promoting mechanism of IL6 and the therapeutic efficacy of tocilizumab: Hypoxia-induced IL6 is a potent autophagy initiator in glioblastoma via the p-STAT3-MIR155-3p-CREBRF pathway.Autophagy. 2016 Jul 2;12(7):1129-52. doi: 10.1080/15548627.2016.1178446. Epub 2016 May 10. Autophagy. 2016. PMID: 27163161 Free PMC article.
-
Tumor STAT1 transcription factor activity enhances breast tumor growth and immune suppression mediated by myeloid-derived suppressor cells.J Biol Chem. 2013 Apr 26;288(17):11676-88. doi: 10.1074/jbc.M112.441402. Epub 2013 Mar 13. J Biol Chem. 2013. PMID: 23486482 Free PMC article.
-
Myeloid suppressor cell depletion augments antitumor activity in lung cancer.PLoS One. 2012;7(7):e40677. doi: 10.1371/journal.pone.0040677. Epub 2012 Jul 16. PLoS One. 2012. PMID: 22815789 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials